Sanofi Secures Vicebio to Advance Next-Gen Respiratory Vaccines

Sanofi has completed the acquisition of Vicebio Ltd, and this will make it stronger in the vaccine portfolio and prove its role as an innovative biopharma leader.

The acquisition combines an exciting early-stage combination vaccine against respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) two significant respiratory infections which impact millions annually.

This addition will help Sanofi to pay more attention to respiratory health and provide doctors and patients with more opportunities.

Also Read: India's Innovative Therapies Set Global Standard at Low Cost

The program obtained is based on the Molecular Clamp technology developed by Vicebio that stabilizes the viral proteins in their pre-fusion state. This increases immunogenicity and allows an improved design of vaccines. In the case of Sanofi, a combination of this technology, combined with its own R&D assets, offers new instruments to shorten the time to develop next-generation vaccines.

The introduction of a non-mRNA RSV vaccine candidate also increases the respiratory product line and expands the market of Sanofi. It is also in line with the long-term objective of the company to offer various forms of vaccines, which will provide healthcare providers with more options as this global demand to stay safe against RSV and HMPV increases.

Sanofi characterizes itself as a biopharma company that is R&D and AI driven and focuses on bettering lives via advanced science. The company uses its in-depth understanding of the immune system to innovate medicines and vaccines currently defending millions of people all over the world. Sanofi is committed to delivering new solutions that have the potential to reach more people over the next years with a scale-designated pipeline which can make a difference in patient lives.